AAVLP HPV vaccine - 2A Pharma
Alternative Names: 2 AP01Latest Information Update: 28 Sep 2024
Price :
$50 *
At a glance
- Originator 2A Pharma
- Class Synthetic vaccines; Virus-like particle vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Human papillomavirus infections
Most Recent Events
- 28 Sep 2024 No recent reports of development identified for phase-I development in Human-papillomavirus-infections(Prevention, In adults) in United Kingdom (IM)
- 05 Sep 2022 AAVLP HPV vaccine is still in phase I trial in Human-papillomavirus-infections (Prevention, In adults) (2A Pharma pipeline, September 2022)
- 29 May 2020 2A Pharma AB completes a phase I trial in Human papillomavirus infections (In adults, Prevention) in United Kingdom (IM) (NCT03929172)